Biofrontera Stock Performance
| BFRI Stock | USD 0.93 0.01 1.06% |
The firm shows a Beta (market volatility) of 0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Biofrontera's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biofrontera is expected to be smaller as well. At this point, Biofrontera has a negative expected return of -0.0359%. Please make sure to confirm Biofrontera's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Biofrontera performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Biofrontera has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Biofrontera is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 17.4 M |
Biofrontera |
Biofrontera Relative Risk vs. Return Landscape
If you would invest 99.00 in Biofrontera on December 17, 2024 and sell it today you would lose (6.40) from holding Biofrontera or give up 6.46% of portfolio value over 90 days. Biofrontera is currently does not generate positive expected returns and assumes 3.8496% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Biofrontera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biofrontera Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biofrontera's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biofrontera, and traders can use it to determine the average amount a Biofrontera's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0093
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BFRI |
Estimated Market Risk
| 3.85 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biofrontera is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biofrontera by adding Biofrontera to a well-diversified portfolio.
Biofrontera Fundamentals Growth
Biofrontera Stock prices reflect investors' perceptions of the future prospects and financial health of Biofrontera, and Biofrontera fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biofrontera Stock performance.
| Return On Equity | -3.91 | ||||
| Return On Asset | -0.46 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.55) % | ||||
| Current Valuation | 6.33 M | ||||
| Shares Outstanding | 8.87 M | ||||
| Price To Book | 1.49 X | ||||
| Price To Sales | 0.23 X | ||||
| Revenue | 34.07 M | ||||
| EBITDA | (18.45 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 1.36 X | ||||
| Total Debt | 5.4 M | ||||
| Book Value Per Share | 0.85 X | ||||
| Cash Flow From Operations | (24.89 M) | ||||
| Earnings Per Share | 1.16 X | ||||
| Total Asset | 27.93 M | ||||
| Retained Earnings | (99.65 M) | ||||
About Biofrontera Performance
By evaluating Biofrontera's fundamental ratios, stakeholders can gain valuable insights into Biofrontera's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biofrontera has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biofrontera has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.Things to note about Biofrontera performance evaluation
Checking the ongoing alerts about Biofrontera for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biofrontera help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biofrontera generated a negative expected return over the last 90 days | |
| Biofrontera has some characteristics of a very speculative penny stock | |
| Biofrontera has high historical volatility and very poor performance | |
| Biofrontera has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 34.07 M. Net Loss for the year was (20.13 M) with profit before overhead, payroll, taxes, and interest of 16.66 M. | |
| Biofrontera currently holds about 31.91 M in cash with (24.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biofrontera has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company shares are held by company insiders |
- Analyzing Biofrontera's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biofrontera's stock is overvalued or undervalued compared to its peers.
- Examining Biofrontera's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biofrontera's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biofrontera's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biofrontera's stock. These opinions can provide insight into Biofrontera's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |